Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas A Butowski

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Journal of Neuro-Oncology|September 15, 2016
Expression and prognostic impact of immune modulatory molecule PD-L1 in meningiomaSeunggu J Han, Gerald Reis, Gary Kohanbash, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Neuro-Oncology Practice|September 27, 2019
Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survivalChristopher H Chapman, Jared H Hara, Annette M Molinaro, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2017
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomaJennifer L Clarke, Annette M Molinaro, Juan R Cabrera, et al.
Journal of Neuro-Oncology|October 24, 2015
Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experienceBrandon S Imber, Steve E Braunstein, Fred Y Wu, et al.
Neuro-Oncology Advances|August 11, 2021
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastomaBenjamin M Ellingson, Kunal Patel, Chencai Wang, et al.
Neuro-Oncology Practice|March 9, 2026
Tele-cognitive rehabilitation for adult lower-grade glioma: An interim prospective pilot feasibility studyChristina Weyer-Jamora, Melissa S Brie, Paige M Bracci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastomaJiaying Chen, Nancy Ann Oberheim Bush, Jennifer A Grabowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Neuro-Oncology Advances|June 18, 2021
Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assayStephen Shuford, Lindsay Lipinski, Ajay Abad, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Journal of Neuro-Oncology|September 15, 2016
Expression and prognostic impact of immune modulatory molecule PD-L1 in meningiomaSeunggu J Han, Gerald Reis, Gary Kohanbash, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Neuro-Oncology Practice|September 27, 2019
Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survivalChristopher H Chapman, Jared H Hara, Annette M Molinaro, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2017
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomaJennifer L Clarke, Annette M Molinaro, Juan R Cabrera, et al.
Journal of Neuro-Oncology|October 24, 2015
Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experienceBrandon S Imber, Steve E Braunstein, Fred Y Wu, et al.
Neuro-Oncology Advances|August 11, 2021
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastomaBenjamin M Ellingson, Kunal Patel, Chencai Wang, et al.
Neuro-Oncology Practice|March 9, 2026
Tele-cognitive rehabilitation for adult lower-grade glioma: An interim prospective pilot feasibility studyChristina Weyer-Jamora, Melissa S Brie, Paige M Bracci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastomaJiaying Chen, Nancy Ann Oberheim Bush, Jennifer A Grabowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Neuro-Oncology Advances|June 18, 2021
Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assayStephen Shuford, Lindsay Lipinski, Ajay Abad, et al.
Pageof 6